These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 33955200)
21. Profibrotic Activation of Human Macrophages in Systemic Sclerosis. Bhandari R; Ball MS; Martyanov V; Popovich D; Schaafsma E; Han S; ElTanbouly M; Orzechowski NM; Carns M; Arroyo E; Aren K; Hinchcliff M; Whitfield ML; Pioli PA Arthritis Rheumatol; 2020 Jul; 72(7):1160-1169. PubMed ID: 32134204 [TBL] [Abstract][Full Text] [Related]
22. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Yoshizaki A; Yanaba K; Ogawa A; Iwata Y; Ogawa F; Takenaka M; Shimizu K; Asano Y; Kadono T; Sato S Arthritis Rheum; 2011 Oct; 63(10):3086-97. PubMed ID: 21618208 [TBL] [Abstract][Full Text] [Related]
23. Downregulated IRF8 in Monocytes and Macrophages of Patients with Systemic Sclerosis May Aggravate the Fibrotic Phenotype. Ototake Y; Yamaguchi Y; Asami M; Komitsu N; Akita A; Watanabe T; Kanaoka M; Kurotaki D; Tamura T; Aihara M J Invest Dermatol; 2021 Aug; 141(8):1954-1963. PubMed ID: 33705797 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630 [TBL] [Abstract][Full Text] [Related]
25. Butyrate Improves Skin/Lung Fibrosis and Intestinal Dysbiosis in Bleomycin-Induced Mouse Models. Park HJ; Jeong OY; Chun SH; Cheon YH; Kim M; Kim S; Lee SI Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803282 [TBL] [Abstract][Full Text] [Related]
26. alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Kokot A; Sindrilaru A; Schiller M; Sunderkötter C; Kerkhoff C; Eckes B; Scharffetter-Kochanek K; Luger TA; Böhm M Arthritis Rheum; 2009 Feb; 60(2):592-603. PubMed ID: 19180474 [TBL] [Abstract][Full Text] [Related]
27. Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis. Mor A; Segal Salto M; Katav A; Barashi N; Edelshtein V; Manetti M; Levi Y; George J; Matucci-Cerinic M Ann Rheum Dis; 2019 Sep; 78(9):1260-1268. PubMed ID: 31129606 [TBL] [Abstract][Full Text] [Related]
28. Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway. Zhu X; Chu H; Jiang S; Liu Q; Liu L; Xue Y; Zheng S; Wan W; Qiu J; Wang J; Zou H J Dermatol Sci; 2017 Aug; 87(2):149-158. PubMed ID: 28532580 [TBL] [Abstract][Full Text] [Related]
29. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Hasegawa M; Hamaguchi Y; Yanaba K; Bouaziz JD; Uchida J; Fujimoto M; Matsushita T; Matsushita Y; Horikawa M; Komura K; Takehara K; Sato S; Tedder TF Am J Pathol; 2006 Sep; 169(3):954-66. PubMed ID: 16936269 [TBL] [Abstract][Full Text] [Related]
30. Wenyang Huazhuo Tongluo formula alleviates pulmonary vascular injury and downregulates HIF-1α in bleomycin-induced systemic sclerosis mouse model. Li K; Wang Q; Lv Q; Guo K; Han L; Duan P; Deng Y; Bian H BMC Complement Med Ther; 2022 Jun; 22(1):167. PubMed ID: 35733188 [TBL] [Abstract][Full Text] [Related]
31. Skin and lung fibrosis induced by bleomycin in mice: a systematic review. Gülle S; Çelik A; Birlik M; Yılmaz O Reumatismo; 2024 Mar; 76(1):. PubMed ID: 38523580 [TBL] [Abstract][Full Text] [Related]
33. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795 [TBL] [Abstract][Full Text] [Related]
34. Myeloid cell-specific deletion of Capns1 prevents macrophage polarization toward the M1 phenotype and reduces interstitial lung disease in the bleomycin model of systemic sclerosis. Zhang L; Zheng D; Yan Y; Yu Y; Chen R; Li Z; Greer PA; Peng T; Wang Q Arthritis Res Ther; 2022 Jun; 24(1):148. PubMed ID: 35729674 [TBL] [Abstract][Full Text] [Related]
35. BMSC-derived extracellular vesicles intervened the pathogenic changes of scleroderma in mice through miRNAs. Jin J; Ou Q; Wang Z; Tian H; Xu JY; Gao F; Hu S; Chen J; Wang J; Zhang J; Lu L; Jin C; Xu GT; Zhao J Stem Cell Res Ther; 2021 Jun; 12(1):327. PubMed ID: 34090522 [TBL] [Abstract][Full Text] [Related]
36. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Taniguchi T; Asano Y; Akamata K; Noda S; Takahashi T; Ichimura Y; Toyama T; Trojanowska M; Sato S Arthritis Rheumatol; 2015 Feb; 67(2):517-26. PubMed ID: 25385187 [TBL] [Abstract][Full Text] [Related]
37. Linagliptin ameliorates pulmonary fibrosis in systemic sclerosis mouse model via inhibition of endothelial-to-mesenchymal transition. Pei B; Zhang N; Pang T; Sun G Mol Cell Biochem; 2022 Apr; 477(4):995-1007. PubMed ID: 34988855 [TBL] [Abstract][Full Text] [Related]
38. The role of B cells in systemic sclerosis. Fukasawa T; Yoshizaki-Ogawa A; Sato S; Yoshizaki A J Dermatol; 2024 Jul; 51(7):904-913. PubMed ID: 38321641 [TBL] [Abstract][Full Text] [Related]
39. The Antifibrotic Effect of α2AP Neutralization in Systemic Sclerosis Dermal Fibroblasts and Mouse Models of Systemic Sclerosis. Kanno Y; Shu E; Kanoh H; Seishima M J Invest Dermatol; 2016 Apr; 136(4):762-769. PubMed ID: 26743600 [TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Maurer B; Distler A; Suliman YA; Gay RE; Michel BA; Gay S; Distler JH; Distler O Ann Rheum Dis; 2014 Oct; 73(10):1880-7. PubMed ID: 23918036 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]